PSA bounce after 125I-brachytherapy for prostate cancer as a favorable prognosticator

Engeler, Daniel S.; Schwab, Christoph; Thöni, Armin; Hochreiter, Werner W.; Prikler, Ladislav; Suter, Stefan; Stucki, Patrick; Schiefer, Johann; Plaßwilm, Ludwig; Schmid, Hans‐Peter; Putora, Paul Martin

doi:10.1007/s00066-015-0860-0

Cited by 11 publications

(9 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A systematic literature review was performed to identify studies reporting PSA bounce post-radiotherapy (see Materials and Methods for details) ( Figure 1 ). The search identified 50 studies including 26,258 patients, which were included in the analysis ( Table 1 ) [ 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 ]. The number of studies and patients stratified by modality is summarized in Table S1 .…”

Section: Resultsmentioning

confidence: 99%

“…The number of studies and patients stratified by modality is summarized in Table S1. Among the 50 studies, eight were prospective observational studies [14,15,17,32,[39][40][41]50] and the others were retrospective observational studies. A meta-analysis showed that the rate of PSA bounce for all studies was 31% (95% confidence interval (CI), 28-33%) (Figure 2).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Characteristics of PSA Bounce after Radiotherapy for Prostate Cancer: A Meta-Analysis

Darwis

Oike

Kubo

et al. 2020

Cancers

View full text Add to dashboard Cite

The rate and characteristics of prostate-specific antigen (PSA) bounce post-radiotherapy remain unclear. To address this issue, we performed a meta-analysis. Reports of PSA bounce post-radiotherapy with a cutoff of 0.2 ng/mL were searched by using Medline and Web of Science. The primary endpoint was the occurrence rate, and the secondary endpoints were bounce characteristics such as amplitude, time to occurrence, nadir value, and time to nadir. Radiotherapy modality, age, risk classification, androgen deprivation therapy, and the follow-up period were extracted as clinical variables. Meta-analysis and univariate meta-regression were performed with random-effect modeling. Among 290 search-positive studies, 50 reports including 26,258 patients were identified. The rate of bounce was 31%; amplitude was 1.3 ng/mL; time to occurrence was 18 months; nadir value was 0.5 ng/mL; time to nadir was 33 months. Univariate meta-regression analysis showed that radiotherapy modality (29.7%), age (20.2%), and risk classification (12.2%) were the major causes of heterogeneity in the rate of bounce. This is the first meta-analysis of PSA bounce post-radiotherapy. The results are useful for post-radiotherapy surveillance of prostate cancer patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Characteristics of PSA Bounce after Radiotherapy for Prostate Cancer: A Meta-Analysis

Darwis

Oike

Kubo

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…One month after the procedure, there was a transient increase in PSA levels. This is a common occurrence after localized prostatic procedures attributed to the sudden release of PSA into the bloodstream by necrotic cells, and it is considered a favorable prognostic factor (24). Beginning in the third month of the follow-up period, a notable decline in PSA levels became evident.…”

Section: Discussionmentioning

confidence: 99%

TransPerineal Laser Ablation (TPLA) Treatment of Focal Low-Intermediate Risk Prostate Cancer

Manenti,

Perretta,

Nezzo

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: this interventional pilot study aimed to evaluate the short-term (3 years) efficacy of focal laser ablation (FLA) in treating the index lesion of low-intermediate risk prostate cancer, along with assessing the safety of the procedure (ClinicalTrials.gov ID NCT04045756). Methods: forty patients aged between 46 and 86 with histologically proven organ-confined prostate cancer and low to intermediate progression risk were included. FLA was performed under percutaneous fusion magnetic resonance/ultrasound guidance in a Day Hospital setting under local anesthesia. Patients underwent regular clinical assessments, PSA measurements, post-procedure MRI scans, and biopsies at 36 months or if positive findings were detected earlier. Statistical analyses were conducted to assess trends in PSA levels and cavity dimensions over time. Results: forty patients were initially included, with 15 lost to follow-up. At 36 months, a mean PSA reduction of 60% was observed, and 80% of MRI scans showed no signs of in-field clinically significant residual/recurrent cancer. Biopsies at 36 months revealed no malignant findings in 20 patients. No deterioration in sexual function or urinary symptoms was recorded. Conclusions: FLA appears to be safe, feasible and effective in the index lesion treatment of low-intermediate risk prostate cancer, with a high rate of tumor eradication and preservation of quality of life.

show abstract

“…One month after the procedure, there was a transient increase in PSA levels. This is a common occurrence after localized prostatic procedures attributed to the sudden release of PSA into the bloodstream by necrotic cells, and it is considered a favorable prognostic factor [26]. Beginning in the third month of the follow-up period, a notable decline in PSA levels became evident.…”

Section: Discussionmentioning

confidence: 99%

Transperineal Laser Ablation (TPLA) Treatment of Focal Low–Intermediate Risk Prostate Cancer

Manenti,

Perretta,

Nezzo

et al. 2024

Cancers

View full text Add to dashboard Cite

Background: This interventional pilot study aimed to evaluate the short-term (3 years) efficacy of focal laser ablation (FLA) in treating the index lesion of low–intermediate-risk prostate cancer, along with assessing the safety of the procedure (ClinicalTrials.gov ID NCT04045756). Methods: Forty patients aged between 46 and 86 with histologically proven organ-confined prostate cancer and low-to-intermediate progression risk were included. FLA was performed under percutaneous fusion magnetic resonance/ultrasound guidance in a Day Hospital setting under local anesthesia. Patients underwent regular clinical and functional assessments through the international index of erectile function (IIEF-5) and the International Prostatism Symptom Score (IPSS), PSA measurements, post-procedure MRI scans, and biopsies at 36 months or if positive findings were detected earlier. Statistical analyses were conducted to assess trends in PSA levels and cavity dimensions over time. Results: Forty patients were initially included, with fifteen lost to follow-up. At 36 months, a mean PSA reduction of 60% was observed, and 80% of MRI scans showed no signs of in-field clinically significant residual/recurrent cancer. Biopsies at 36 months revealed no malignant findings in 20 patients. No deterioration in sexual function or urinary symptoms was recorded. Conclusions: FLA appears to be safe, feasible, and effective in the index lesion treatment of low–intermediate-risk prostate cancer, with a high rate of tumor eradication and preservation of quality of life.

show abstract

PSA bounce after 125I-brachytherapy for prostate cancer as a favorable prognosticator

Abstract: In most cases, an early increase in PSA after BT indicates PSA bounce and is associated with a lower risk of biochemical failure.

Cited by 11 publications

References 22 publications

Characteristics of PSA Bounce after Radiotherapy for Prostate Cancer: A Meta-Analysis

Characteristics of PSA Bounce after Radiotherapy for Prostate Cancer: A Meta-Analysis

TransPerineal Laser Ablation (TPLA) Treatment of Focal Low-Intermediate Risk Prostate Cancer

Transperineal Laser Ablation (TPLA) Treatment of Focal Low–Intermediate Risk Prostate Cancer

Contact Info

Product

Resources

About